Galectin Therapeutics (NASDAQ:GALT) is a biotechnology company deeply involved in the development of therapies that target galectin proteins to treat fibrotic liver disease and cancer. With a primary focus on utilizing its expertise in galectin science, Galectin Therapeutics endeavors to create innovative treatments that can significantly improve the lives of patients struggling with these severe conditions. The company's key projects include the development of its flagship compound, belapectin, for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis and cirrhosis, a testament to its commitment to addressing unmet medical needs. Through its sustained research and development efforts, Galectin Therapeutics aims to establish a leading position in the field of galectin inhibitors, striving to bring breakthrough solutions from the lab to the clinic.